Payment and coverage for immunohistochemistry (IHC) stains are facing increased scrutiny from both commercial and government payers. For pathology groups and laboratories, this heightened attention has translated into tighter policy language, expanded documentation requirements, and growing use of utilization management tools that directly impact reimbursement.
As payers refine their approach to IHC utilization, pathology practices and clinical laboratories must stay informed of emerging policy interpretations and ensure that clinical and billing workflows remain aligned.
Growing Policy Limitations on IHC Stains
Across the payer landscape, pathology providers are encountering expanded coverage limitations related to immunohistochemical and special histochemical stains.
A recurring theme in payer policies is the use of frequency edits to restrict reimbursement for multiple IHC stains performed on a single specimen. While these policies often acknowledge the clinical value of IHC in diagnostic decision-making, they increasingly require pathologists to justify not only why a stain is ordered, but how many stains are considered reasonable for a given case.
In practice, these requirements introduce additional administrative burden and elevate denial risk when documentation does not explicitly align with payer-specific coverage language. Even clinically appropriate staining may be vulnerable to nonpayment if documentation does not sufficiently support medical necessity as defined by the payer.
IHC Reclassified as Genetic Testing Under New Payer Policy
In a recent audit review, Lighthouse’s RCM Consulting team uncovered a notable UnitedHealthcare / Optum policy application in Utah. Under this interpretation, certain IHC stains (CPT® 88341 and 88342) are treated as genetic testing unless they are tied to a dermatologic diagnosis.
This classification carries significant consequences. When treated as genetic testing, these IHC stains become subject to prior authorization requirements, a step not traditionally associated with routine anatomic pathology workflows.
For pathology practices, this creates both operational and financial risk. IHC stains may be performed as part of a standard diagnostic evaluation, only to be denied later due to the absence of prior authorization, often after services have already been rendered and results finalized.
Importantly, this interpretation reflects a payer- and region-specific policy position, underscoring the need for practices to monitor coverage rules at a granular level rather than relying solely on national norms or historical billing patterns.
The Role of Audits in Identifying Reimbursement Risk
Notably, this policy interpretation was not identified through routine claim denials alone—it was uncovered through a proactive audit. This highlights the critical role that regular billing and policy audits play in detecting emerging payer positions before they result in widespread revenue leakage.
For pathology groups, audits can help:
- Identify payer-specific interpretations that differ from industry standards
- Assess exposure related to prior authorization, frequency edits, and documentation gaps
- Evaluate ordering and billing patterns against current coverage policies
- Adjust clinical documentation and billing practices proactively rather than reactively
By identifying risks early, practices can implement targeted workflow and documentation adjustments before denial trends become systemic.
What This Means for Pathology Groups
As payer oversight of IHC utilization increases, pathology groups should anticipate:
- Greater emphasis on detailed medical necessity documentation
- Expanded use of utilization management tools, including frequency limits
- Potential prior authorization requirements for services historically exempt from such controls
- Increased financial exposure tied to payer-specific policy interpretations
These trends reinforce the importance of close alignment between clinical decision-making, pathology reporting, and revenue cycle operations.
Looking Ahead: Staying Ahead of Payer Scrutiny
As payers continue to refine coverage policies, pathology groups can expect ongoing pressure surrounding IHC utilization, documentation, and reimbursement. The reclassification of IHC stains as genetic studies, particularly when paired with prior authorization requirements, signals a broader shift toward more aggressive utilization management in anatomic pathology.
For pathology practices navigating this evolving landscape, proactive review and continuous monitoring are no longer optional; they are essential components of sustainable laboratory revenue cycle management.
Contact Lighthouse for a complimentary consultation to learn more about our audit process.
